Surf Wiki
Save to docs
general/monoclonal-antibodies-for-tumors

From Surf Wiki (app.surf) — the open knowledge base

Indatuximab ravtansine

Chemical compound

Chemical compound

| Drugs.com = | elimination_half-life =

Indatuximab ravtansine (BT062) is an immunomodulator and antineoplastic antibody-drug conjugate.

It is the anti-CD138 chimerized MAb (nBT062) linked to the maytansinoid DM4.

It is being investigated as part of a treatment for multiple myeloma.

Clinical trials

Multiple Myeloma

Preliminary data has been reported in 2013 from an early stage clinical trial in combination with Lenalidomide and Dexamethasone.

Other

, it is in clinical trials for triple negative metastatic breast cancer and metastatic urinary bladder cancer.

Mechanism of action

CD138 (Syndecan-1) is highly overexpressed on various solid tumors and in hematological malignancies, and represents one of the most specific target antigens for identification of multiple myeloma (MM) cells. The antibody part binds to CD138 on the target cells and then the DM4 kills the cell.

References

References

  1. [http://www.myelomabeacon.com/resources/mtgs/ash2013/abs/758/ Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients]
  2. (January 2026)
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

monoclonal-antibodies-for-tumors antibody-drug-conjugates experimental-cancer-drugs
Want to explore this topic further?

Ask Mako anything about Indatuximab ravtansine — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report